Abbott today announced the US Food and Drug Administration (FDA) approval of the XIENCE™ V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
Manufactured in Clonmel, XIENCE V is a next-generation drug eluting stent system, which will be launched in the United States immediately.
CONNECT WITH US TODAY
Be the first to know the latest news and updates
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Push Notifications
By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.
Sign UpNewsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Newsletter
Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.
Sunday, December 7, 2025 - 5:00 PM
Sunday, December 7, 2025 - 9:00 PM
Sunday, December 7, 2025 - 10:00 PM
